ME02576B - Derivati tetrahidropirolotiazina kao inhibitori bace - Google Patents

Derivati tetrahidropirolotiazina kao inhibitori bace

Info

Publication number
ME02576B
ME02576B MEP-2017-4A MEP20174A ME02576B ME 02576 B ME02576 B ME 02576B ME P20174 A MEP20174 A ME P20174A ME 02576 B ME02576 B ME 02576B
Authority
ME
Montenegro
Prior art keywords
compound
salt
pharmaceutically acceptable
acceptable salt
group
Prior art date
Application number
MEP-2017-4A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Eli Lilly And Company C/O
Eli Lillyand Company c/o
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ME02576B publication Critical patent/ME02576B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2017-4A 2012-10-26 2017-02-10 Derivati tetrahidropirolotiazina kao inhibitori bace ME02576B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718728P 2012-10-26 2012-10-26
PCT/US2013/065418 WO2014066132A1 (en) 2012-10-26 2013-10-17 Bace inhibitors
EP13785730.6A EP2912041B1 (en) 2012-10-26 2013-10-17 Tetrahydropyrrolothiazine derivatives as bace inhibitors

Publications (1)

Publication Number Publication Date
ME02576B true ME02576B (me) 2017-06-20

Family

ID=49515508

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-4A ME02576B (me) 2012-10-26 2017-02-10 Derivati tetrahidropirolotiazina kao inhibitori bace

Country Status (17)

Country Link
US (1) US9328124B2 (cg-RX-API-DMAC7.html)
EP (1) EP2912041B1 (cg-RX-API-DMAC7.html)
JP (1) JP6243921B2 (cg-RX-API-DMAC7.html)
CN (1) CN104755484B (cg-RX-API-DMAC7.html)
CA (1) CA2886507C (cg-RX-API-DMAC7.html)
CY (1) CY1118623T1 (cg-RX-API-DMAC7.html)
DK (1) DK2912041T3 (cg-RX-API-DMAC7.html)
ES (1) ES2616835T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170025T1 (cg-RX-API-DMAC7.html)
HU (1) HUE031764T2 (cg-RX-API-DMAC7.html)
LT (1) LT2912041T (cg-RX-API-DMAC7.html)
ME (1) ME02576B (cg-RX-API-DMAC7.html)
PL (1) PL2912041T3 (cg-RX-API-DMAC7.html)
PT (1) PT2912041T (cg-RX-API-DMAC7.html)
RS (1) RS55561B1 (cg-RX-API-DMAC7.html)
SI (1) SI2912041T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014066132A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201446758A (zh) 2013-03-01 2014-12-16 Amgen Inc 作爲β-分泌酶抑制劑的全氟化5,6-二氫-4H-1,3-□-2-胺化合物及其用途
HK1217486A1 (zh) 2013-03-08 2017-01-13 Amgen Inc. 作爲β-分泌酶抑制剂的全氟化环丙基稠合的1,3-恶嗪-2-胺化合物以及其使用方法
TWI684452B (zh) * 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
AU2015301028B2 (en) 2014-08-08 2019-09-26 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
US10246429B2 (en) 2015-08-06 2019-04-02 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
US11548903B2 (en) 2016-12-15 2023-01-10 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
EP3555084B1 (en) 2016-12-15 2022-03-16 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
MA52722A (fr) 2016-12-15 2021-04-14 Amgen Inc Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
AU2017376446B2 (en) 2016-12-15 2021-10-14 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
AU2017378316B2 (en) 2016-12-15 2021-04-01 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
CN106632001A (zh) * 2016-12-28 2017-05-10 山东诚汇双达药业有限公司 一种4‑(溴乙酰基)吡啶氢溴酸盐的制备方法
CN110452179A (zh) * 2019-06-25 2019-11-15 南京普锐达医药科技有限公司 一种2-氯-4-甲氧基-5-氰基嘧啶的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0612072A2 (pt) * 2005-06-14 2010-10-19 Schering Corp inibidores da aspartil protease
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
US20100317850A1 (en) * 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
MX2010011563A (es) 2008-04-22 2010-11-12 Schering Corp Compuestos 2-imino-3-metil pirrolo pirimidinona fenil-sustituidos como inhibidores de enzima de escision de proteina precursora amiloide sitio beta-1, composiciones y su uso.
AU2009258496B8 (en) 2008-06-13 2014-06-26 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
MX2011003189A (es) 2008-09-30 2011-04-27 Eisai R&D Man Co Ltd Nuevo derivado de aminodihidrotiazina fusionada.
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) * 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
EP2511269A4 (en) * 2009-12-11 2013-04-24 Shionogi & Co FUSED HETEROCYCLIC COMPOUND HAVING AN AMINO GROUP
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012162334A1 (en) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
JO3143B1 (ar) 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين
GB201212871D0 (en) * 2012-07-20 2012-09-05 Eisai Ltd Novel compounds
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物

Also Published As

Publication number Publication date
US9328124B2 (en) 2016-05-03
EP2912041B1 (en) 2016-12-14
PL2912041T3 (pl) 2017-06-30
US20150232483A1 (en) 2015-08-20
CA2886507C (en) 2016-09-20
EP2912041A1 (en) 2015-09-02
HRP20170025T1 (hr) 2017-03-10
SI2912041T1 (sl) 2017-02-28
JP2015535247A (ja) 2015-12-10
HUE031764T2 (en) 2017-07-28
WO2014066132A1 (en) 2014-05-01
ES2616835T3 (es) 2017-06-14
CY1118623T1 (el) 2017-07-12
PT2912041T (pt) 2017-02-13
RS55561B1 (sr) 2017-05-31
CN104755484A (zh) 2015-07-01
CA2886507A1 (en) 2014-05-01
DK2912041T3 (en) 2017-02-27
LT2912041T (lt) 2017-03-10
CN104755484B (zh) 2016-02-17
JP6243921B2 (ja) 2017-12-06

Similar Documents

Publication Publication Date Title
ME02576B (me) Derivati tetrahidropirolotiazina kao inhibitori bace
ME02910B (me) Spojevi tetrahidropirolotiazina
HRP20160674T1 (hr) Tetrahidropirolotiazinski spojevi
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
JO3146B1 (ar) مشتقات غير متجانسة الحلقية و استخدامها في علاج الاضطرابات العصبية
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
GEP20156389B (en) Oxazolidin-2-one compounds and their usage as pi3ks inhibitors
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
PE20151651A1 (es) Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina
ME02840B (me) Spojevi fenoksietilpiperidina
RU2013142012A (ru) 1,4 тиазепины/сульфоны в качестве ингибиторов васе1 и(или) васе2
HRP20161379T1 (hr) Inhibitori hepatitis c virusa
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
WO2012107706A8 (en) Phenothiazine diaminium salts and their use
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
HRP20241145T1 (hr) Biciklički aza spojevi kao agonisti muskarinskih receptora
EA201490491A1 (ru) Производные 2-амино-4-(пиридин-2-ил)-5,6-дигидро-4h-1,3-оксазинов и их использование в качестве ингибиторов bace-1 и/или bace-2
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
HRP20180237T4 (hr) Metode za liječenje hcv-a
NZ627827A (en) Antiviral combinations involving (3s, 11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
EA201591804A1 (ru) Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы